title: Where Do We Stand With Aspirin for the Prevention of Colorectal Cancer? The USPSTF Recommendations.
authors.affiliation: Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: achan@mgh.harvard.edu.
authors.forename: Andrew T
authors.initials: AT
authors.lastname: Chan
authors.affiliation: Stanford University School of Medicine, Stanford, California. Electronic address: uri.ladabaum@stanford.edu.
authors.forename: Uri
authors.initials: U
authors.lastname: Ladabaum
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage* / Q000009:adverse effects; D018890:Chemoprevention / Q000592:standards; D015179:Colorectal Neoplasms / Q000401:mortality* / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic / Q000592:standards*; D011315:Preventive Medicine / Q000592:standards; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States
chemical_list: D001241:Aspirin